8-K: Seres Therapeutics Reports Q2 2026 Results, Focuses on SER-155

Seres Therapeutics announced second quarter 2026 financial results, highlighting positive clinical data for its SER-155 program in immune checkpoint inhibitor-related enterocolitis and detailing significant efforts to reduce operational costs.

Summary

• Seres Therapeutics reported its financial results for the second quarter ended June 30, 2026.
• The company announced positive topline results from an investigator-sponsored trial (IST) of SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC), where 80% of participants achieved an immunosuppressive-free clinical response.
• Seres is actively seeking potential partners and capital to advance its SER-155 programs, including for irEC and for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT).
• The company has entered into an agreement to terminate its lease at 200 Sidney Street early, further reducing ongoing facility-related cash costs, following a similar restructuring in June 2026.
• Net income for Q2 2026 was $4.6 million, a significant improvement from a net loss of $19.9 million in Q2 2025, largely due to a $25 million gain on the sale of the VOWST business.
• Research and development expenses decreased to $9.1 million in Q2 2026 from $12.9 million in Q2 2025.
• General and administrative expenses also decreased to $7.1 million in Q2 2026 from $10.3 million in Q2 2025.
• As of June 30, 2026, the company had $15.6 million in cash and cash equivalents, with an expected operational runway through the first quarter of 2027, excluding potential future capital raises.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with positive clinical data for SER-155 and significant cost-saving measures, but tempered by the ongoing need for capital and a short cash runway.

Positives

• 80% of SER-155 recipients in an investigator-sponsored trial achieved an immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC).
• The IST data for SER-155 in irEC support its potential to allow patients to continue cancer therapy.
• Seres is actively engaging potential partners for its SER-155 programs.
• Agreement to terminate the Sidney Street lease early will significantly reduce ongoing facility-related cash costs starting in 2027.
• Net income of $4.6 million in Q2 2026, a substantial improvement from a net loss of $19.9 million in Q2 2025, driven by a $25 million gain from the VOWST business sale.
• Reduced operating expenses: R&D expenses decreased by $3.8 million and G&A expenses decreased by $3.2 million year-over-year in Q2 2026.
• The company received $12.5 million from Nestl on July 1, 2026, and expects another $12.5 million on October 1, 2026, related to the VOWST business sale.

Negatives

• As of June 30, 2026, cash and cash equivalents stood at $15.6 million, indicating a need for additional funding.
• The company expects to fund operations only through the first quarter of 2027, excluding any potential future capital raises.
• A $5.8 million impairment charge was recorded related to the early termination of a portion of the lease at 101 Cambridgepark Drive.
• The company has incurred significant losses historically and may never become profitable.
• The company faces the risk of not being able to satisfy continued listing rules from The Nasdaq Stock Market LLC.

Risks

• The company's need for additional funding is a significant risk.
• The ability to continue as a going concern is dependent on securing future financing.
• The company has incurred significant losses and may never achieve profitability.
• Cost reduction actions may not achieve their intended benefits, including an extended cash runway.
• The company has a limited operating history.
• There is a risk of not realizing the anticipated benefits of the VOWST sale and facing new challenges as a smaller company.
• The company may receive notice of failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC.
• The company's novel approach to therapeutic intervention carries inherent risks.

Future Outlook

The company is actively seeking partnerships and capital to advance its SER-155 programs for irEC and allo-HCT, and to support the development of SER-603 for inflammatory bowel disease. Operational runway is projected through Q1 2027, excluding additional funding.

Management Comments

• "We are very pleased with the recent progress at Seres, including the positive topline data from the investigator-sponsored trial of SER-155 in irEC conducted by MSK, announced last month."
• "The study demonstrated that 80% of participants achieved an immunosuppressive-free clinical response at day 15, and the accompanying pharmacology data reinforced that our live biotherapeutic operated as designed, including by repairing the mucosal epithelial barrier."
• "SER-155 to treat irEC, a frequent and often severe side effect of widely used immune checkpoint inhibitor (ICI) cancer treatment, represents a meaningful therapeutic and commercial opportunity..."
• "We are engaging potential partners, including companies with ICI franchises, as we evaluate the clinical development pathway in this indication and consider sources of financing."
• "Terminating our Sidney Street lease will substantially reduce our future lease obligations and will further lower our ongoing annual fixed costs beginning in 2027."
• "Together with the lease restructuring we announced in June, this transaction reflects our continued focus on rigorous financial discipline, while we maintain the operational infrastructure needed to advance our live biotherapeutic pipeline, including our Phase 2-ready SER-155 program in allo-HCT."

Industry Context

StockSavvy.ai notes that Seres Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on live biotherapeutics. The positive data for SER-155 in irEC addresses a significant unmet need for patients undergoing cancer immunotherapy, a growing area of treatment. The company's strategic focus on partnerships and cost reduction aligns with industry trends for smaller biotechs navigating development pathways and seeking to extend their cash runway.

Related Party Transactions

• Accounts receivable due from SPN (related party) of $25,000 as of June 30, 2026.
• Accrued liabilities due to SPN (related party) of $3,278 as of June 30, 2026.
• Other income (expense) includes reimbursements from SPN (related party) for transition services.

Stakeholder Impact

• Shareholders: The need for capital and a short cash runway may lead to dilution if equity financing is pursued. Positive clinical data for SER-155 offers potential future upside.
• Creditors: The company's financial position and cash runway are key considerations for creditors.
• Employees: Cost reduction measures, including facilities cost savings, may impact operational scale and potentially employment.
• Partners/Collaborators: The company's active engagement with potential partners indicates a strategy to leverage external resources for pipeline advancement.

Next Steps

• Evaluate the clinical development strategy for SER-155 in irEC in consultation with Key Opinion Leaders (KOLs).
• Engage potential partners and seek capital to advance SER-155 programs for irEC and allo-HCT.
• Advance IND-enabling activities for SER-603 for inflammatory bowel disease.
• Design and potentially initiate a Phase 1b trial for SER-428 in medical ICU patients.
• Report accounting for the Sidney Street lease termination in the third quarter 2026 results.

Key Dates

Recommendation

The positive clinical data for SER-155 in irEC is a significant development, addressing a clear unmet need. However, the company's precarious cash position and reliance on future capital raises, coupled with a short operational runway, present substantial risks. While cost-saving measures are positive, they do not fundamentally alter the need for external funding to advance key programs. Therefore, a 'hold' recommendation is appropriate, pending further clarity on partnerships, financing, and clinical development progress.

Keywords

SER-155, irEC, live biotherapeutics, immune checkpoint inhibitor, enterocolitis, allo-HCT, biotechnology, clinical trial